Table 3.

Efficacy and Grade ≥ 3 AE between nab-paclitaxel vs sb-paclitaxel or docetaxel each.

Efficacy	Subgroup	No. of studies	OR/HR (95% CI)	p-value	I2 (%)
ORR2–5,10	nab-paclitaxel vs sb-paclitaxel	2	2.39 (1.69–3.37)	<0.001†	0
	nab-paclitaxel vs docetaxel	2	1.38 (0.90–2.11)	0.14	0
DCR3–5,10	nab-paclitaxel vs sb-paclitaxel	1	1.89 (1.07–3.35)	0.03†	—
	nab-paclitaxel vs docetaxel	2	2.48 (1.39–4.44)	0.002†	0
PFS2–5,10	nab-paclitaxel vs sb-paclitaxel	2	0.75 (0.62–0.90)	0.002†	0
	nab-paclitaxel vs docetaxel	2	0.80 (0.32–1.98)	0.63	88
OS2–5,10	nab-paclitaxel vs sb-paclitaxel	2	0.94 (0.78–1.13)	0.53	0
	nab-paclitaxel vs docetaxel	2	0.73 (0.54–0.99)	0.04†	0
Grade ≥ 3 AE
Neutropenia2–5,10	nab-paclitaxel vs sb-paclitaxel	2	0.70 (0.34–1.42)	0.32	78
	nab-paclitaxel vs docetaxel	2	0.07 (0.03–0.16)	<0.001†	0
Leukopenia2,3,10	nab-paclitaxel vs sb-paclitaxel	2	0.92 (0.57–1.49)	0.73	0
	nab-paclitaxel vs docetaxel	1	0.15 (0.07–0.33)	<0.001†	—
Sensory neuropathy2–5,10	nab-paclitaxel vs sb-paclitaxel	2	2.56 (0.62–10.64)	0.20	73
	nab-paclitaxel vs docetaxel	2	3.17 (1.20–8.33)	0.02†	51
Fatigue2,4,5,10	nab-paclitaxel vs sb-paclitaxel	1	4.82 (1.37–17.02)	0.01†	—
	nab-paclitaxel vs docetaxel	2	0.50 (0.04–7.01)	0.60	61
DDR3–5,10	nab-paclitaxel vs sb-paclitaxel	1	1.37 (0.30–6.29)	0.68	—
	nab-paclitaxel vs docetaxel	2	0.67 (0.41–1.09)	0.10	0

^†Statistically significant when p < 0.05. Analyzed using random effects model

Abbreviations: nab, nanoparticle albumin-bound; sb, solvent-based; OR, odds ratio (for ORR, DCR, AEs and DDR); HR, hazard ratio (for PFS and OS); –, not defined.